CMV

COMMUNIQUÉS West-GlobeNewswire

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
12/08/2025
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as [...]
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
12/08/2025
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy [...]
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
12/08/2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Completed enrollment of Phase 2 MoonStone trial in Relapsing Multiple Sclerosis; results [...]
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
12/08/2025
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025 Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved Public [...]
Quipt Home Medical Partners With Three Major Health Systems to Form Strategic Joint Venture
12/08/2025
Transaction Adds $60 Million in Revenue, 29 Locations, Deep Health System Relationships, and Marks Entry Into Michigan Market CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“ Quipt ” or the “ [...]
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
12/08/2025
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company [...]
Enable Injections Announces enFuse® System Regulatory Approval in Brazil and MRHA Medical Device Registration in the UK
12/08/2025
CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® on-body drug delivery system, announced today that the [...]
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
12/08/2025
Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating alternate dose [...]
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
12/08/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12, 2025 [...]
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
12/08/2025
Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended to support [...]
57 Confluent Health Physical and Occupational Therapists Receive Board-Certified Clinical Specialist Credential
12/08/2025
Certification Reflects Highest Level of Advanced Clinical Practice in Musculoskeletal Care LOUISVILLE, Ky., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Fifty-seven Physical and Occupational Therapists from Confluent Health’s [...]
Hydreight Posts Record VSDHOne Growth, Ahead of 2025 Targets
12/08/2025
June and July orders surge; Perfect Scripts + 503B partnership boosts scale VANCOUVER, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or [...]
Cerevance to Participate in Piper Sandler Virtual CNS Symposium
12/08/2025
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today [...]
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
12/08/2025
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain after discontinuation [...]
electroCore Names Kelly Benning, Accomplished Healthcare Executive, as SVP of Truvaga
12/08/2025
ROCKAWAY, N.J., Aug. 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Kelly Benning has been hired as the Senior Vice [...]
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
12/08/2025
WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for [...]
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
12/08/2025
Early evidence of disease control was observed in the ongoing Phase 1 ACESOT-1051 trial, with three patients achieving stable disease in the 70 mg and 100 mg cohorts treated with the WEE1 inhibitor, APR-1051 $16.5 [...]
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
12/08/2025
Dr. Tweezer-Zaks Transitions from the Company’s Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd [...]
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
12/08/2025
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported by [...]

Pages